OncoMatch/Clinical Trials/NCT05890352
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Is NCT05890352 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tafasitamab and Lenalidomide for grade 3b follicular lymphoma.
Treatment: Lenalidomide · Tafasitamab · Tazemetostat · Zanubrutinib — This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Allowed: BCL2 rearrangement
Allowed: BCL6 rearrangement
Allowed: MYC rearrangement
Performance status
ZUBROD 0–3
Prior therapy
Must have received: systemic multiagent regimen for aggressive lymphoma
Participants must have had 1-5 prior systemic treatment regimens including one systemic multiagent regimen for aggressive lymphoma
Cannot have received: tafasitamab
Participants must not have received prior treatment with tafasitamab and/or lenalidomide
Cannot have received: lenalidomide
Participants must not have received prior treatment with tafasitamab and/or lenalidomide
Cannot have received: BTK inhibitor
Participants must not have had prior BTK inhibitor or tazemetostat
Cannot have received: tazemetostat
Participants must not have had prior BTK inhibitor or tazemetostat
Lab requirements
Blood counts
ANC >= 1.0 x 10^3/uL (>= 0.75 x 10^3/uL if bone marrow involvement); platelets >= 75 x 10^3/uL (>= 50 x 10^3/uL if bone marrow involvement)
Kidney function
calculated creatinine clearance >= 30 mL/min using Cockcroft-Gault Formula
Liver function
AST <= 3 x IULN, ALT <= 3 x IULN (<= 5 x IULN if lymphomatous involvement of liver); total bilirubin <= 1.5 x IULN (<= 5 x IULN if lymphomatous involvement of liver)
Cardiac function
Participants with cardiac disease or prior cardiotoxic agents: NYHA class 2B or better
AST <= 3 x IULN, ALT <= 3 x IULN (<= 5 x IULN if lymphomatous involvement of liver); total bilirubin <= 1.5 x IULN (<= 5 x IULN if lymphomatous involvement of liver); calculated creatinine clearance >= 30 mL/min; ANC >= 1.0 x 10^3/uL (>= 0.75 x 10^3/uL if bone marrow involvement); platelets >= 75 x 10^3/uL (>= 50 x 10^3/uL if bone marrow involvement); NYHA class 2B or better if cardiac risk
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner University Medical Center - Tucson · Tucson, Arizona
- University of Arizona Cancer Center-North Campus · Tucson, Arizona
- Tower Cancer Research Foundation · Beverly Hills, California
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope Seacliff · Huntington Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify